IJCRT Peer-Reviewed (Refereed) Journal as Per New UGC Rules.
ISSN Approved Journal No: 2320-2882 | Impact factor: 7.97 | ESTD Year: 2013
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 7.97 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(CrossRef DOI)
| IJCRT Journal front page | IJCRT Journal Back Page |
Paper Title: INVESTIGATE THE EFFECT OF MOMORDICA CHARANTIA AND SPONDIAS MOMBIN ON DIABETIC RATS AGAINST STZ INDUCED DIABETES
Author Name(s): Dhiraj Kumar, Neha Jain, Supriya Singh, Paras Jain, Sarita Joshi
Published Paper ID: - IJCRT21X0275
Register Paper ID - 268921
Publisher Journal Name: IJPUBLICATION, IJCRT
DOI Member ID: 10.6084/m9.doi.one.IJCRT21X0275 and DOI :
Author Country : Indian Author, India, 201015 , Ghaziabad, 201015 , | Research Area: Pharmacy All Published Paper URL: http://ijcrt.org/viewfull.php?&p_id=IJCRT21X0275 Published Paper PDF: download.php?file=IJCRT21X0275 Published Paper PDF: http://www.ijcrt.org/papers/IJCRT21X0275.pdf
Title: INVESTIGATE THE EFFECT OF MOMORDICA CHARANTIA AND SPONDIAS MOMBIN ON DIABETIC RATS AGAINST STZ INDUCED DIABETES
DOI (Digital Object Identifier) :
Pubished in Volume: 12 | Issue: 9 | Year: September 2024
Publisher Name : IJCRT | www.ijcrt.org | ISSN : 2320-2882
Subject Area: Pharmacy All
Author type: Indian Author
Pubished in Volume: 12
Issue: 9
Pages: o836-o875
Year: September 2024
Downloads: 406
E-ISSN Number: 2320-2882
ABSTRACT Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels. This study aimed to investigate the potential antidiabetic effects of Momordica charantia (bitter melon) and Spondias mombin (yellow mombin) on streptozotocin (STZ)-induced diabetic rats. The experiment involved six groups of rats: a normal control group, a diabetic control group, a group treated with Metformin as standard drug,a group treated with Momordica charantia, and a group treated with Spondias mombin and a group treated with combination of both herbal drug Spondias mombin and Momordica charantia . Diabetes was induced in the rats using a single intraperitoneal injection of STZ. The treatment groups received oral doses of the respective plant extracts for a duration of four weeks. The results demonstrated that both Momordica charantia and Spondias mombin exhibited significant antidiabetic effects in the diabetic rats. Treatment with these plant extracts resulted in a reduction in fasting blood glucose levels, compared to the diabetic control group. Furthermore, the plant extract-treated groups showed improved glucose tolerance and increased insulin sensitivity compared to the diabetic control group. Biochemical analysis revealed that the plant extracts effectively restored altered lipid profile parameters, including total cholesterol, triglycerides, and low-density lipoprotein cholesterol, towards normal levels. Moreover, treatment with Momordica charantia and Spondias mombin significantly attenuated oxidative stress by increasing antioxidant enzyme activity and reducing malondialdehyde levels. Histopathological examination of pancreatic tissues showed that both plant extracts preserved pancreatic architecture and reduced STZ-induced damage, such as beta-cell degeneration and inflammatory cell infiltration. In conclusion, the findings of this study indicate that Momordica charantia and Spondias mombin have potential antidiabetic properties and may provide beneficial effects in managing diabetes. These plant extracts exhibited hypoglycemic, hypolipidemic, antioxidant, and pancreatic protective effects in STZ-induced diabetic rats. Further research is warranted to explore the underlying mechanisms and identify active compounds responsible for these effects, which could lead to the development of novel therapeutic interventions for diabetes management.
Licence: creative commons attribution 4.0
Keywords: Momordica charantia, Spondias mombin, Streptozotocin, Diabetic Mellitus, T1DM, T2DM.

